FDA Officially Recommends Removal Of Interchangeability Designation From Biosimilar Labels

Agency Previously Floated The Idea In Draft Guidance In September

 
• By Chloe Kent

The US Food and Drug Administration has recommended that biosimilar drugs all use the same biosimilarity statement on their product information. Interchangeable products currently employ a separate interchangeability statement.

Pharmacist serving a patient at the counter
Interchangability relates to pharmacy-level substitution, meaning the information may be more suitable in the Purple Book rather than on labeling • Source: Shutterstock

The US Food and Drug Administration has recommended that the prescribing information for all biosimilar drugs marketed in the country display a uniform biosimilarity statement, including interchangeable biosimilars which currently display an interchangeability statement instead.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Celltrion Celebrates Interchangeability Designation For Humira Biosimilar In The US

 
• By Urtė Fultinavičiūtė

Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.

Samsung Bioepis Reevaluating Approach To Biosimilars

 
• By Jessica Merrill

The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Cardinal Looks Ahead To A New Decade For US Biosimilars

 
• By Dave Wallace

In the wake of a report marking 10 years since the first US biosimilar launch, Cardinal Health’s Dracey Poore speaks to Generics Bulletin about the successes seen so far and the obstacles that must be overcome if the market is to thrive in the decade ahead.

More from Products